Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra‐High DoSes (ICARUS)

PURPOSE: Immune checkpoint inhibitors improve survival in metastatic diseases for some cancers. Multisite SBRT with pembrolizumab (SBRT + Pembro) was shown to be safe with promising local control using biologically effective doses (BEDs) = 95–120 Gy. Increased BED may improve response rate; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rokni, Michelle B., Pointer, Kelli B., George, Jonathan, Luke, Jason J., Chmura, Steven J., Redler, Gage
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Radiation Oncology Physics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984482/
https://www.ncbi.nlm.nih.gov/pubmed/33626240
http://dx.doi.org/10.1002/acm2.13204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984482/
https://www.ncbi.nlm.nih.gov/pubmed/33626240
http://dx.doi.org/10.1002/acm2.13204

Ejemplares similares